Streetbeat News

Analyst Ratings

TCPC

Wells Fargo analyst Timothy O'Shea has maintained an Equal-Weight rating on BlackRock TCP Capital Corp (TCPC) and increased the price target from $11 to $11.5.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:47 pm

BKCC

Wells Fargo analyst Timothy O'Shea has maintained an Equal-Weight rating on BlackRock Capital Investment Corporation (BKCC) and increased the price target from $3.50 to $3.75.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:46 pm

POR

UBS analyst Gregg Orrill upgraded Portland Gen Electric (NYSE:POR) from Neutral to Buy, while also lowering the price target from $47 to $45.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:46 pm

BBDC

Wells Fargo analyst Finian O'Shea has maintained an Equal-Weight rating on Barings BDC (NYSE:BBDC) and increased the price target from $8.50 to $8.75.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:46 pm

BCSF

Wells Fargo analyst Timothy O'Shea has maintained an Equal-Weight rating on Bain Capital Specialty (BCSF) and increased the price target from $13.75 to $14.5.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:45 pm

ARCC

Wells Fargo analyst Timothy O'Shea has maintained an Equal-Weight rating on Ares Capital (NASDAQ:ARCC) and increased the price target from $19 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:44 pm

PLL

Piedmont Lithium's stock (PLL) trades lower following a downgrade from TD Cowen from Outperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:44 pm

OFG

Wells Fargo analyst Timur Braziler has maintained an Overweight rating on OFG Bancorp (NYSE:OFG) and increased the price target from $40 to $41.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:43 pm

FHB

Wells Fargo analyst Jared Shaw has maintained an Underweight rating on First Hawaiian (NASDAQ:FHB) but increased the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:43 pm

VIR

Vir Biotechnology's stock is trading lower following a downgrade by JP Morgan from Overweight to Neutral, with a reduced price target from $23 to $9.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:42 pm